Mazouni Chafika, Fina Frédéric, Romain Sylvie, Ouafik L'houcine, Bonnier Pascal, Martin Pierre-Marie
Transfer Laboratory of Biological Oncology, Public Assistance Hospitals of Marseille, Northern Faculty of Medicine, Marseille ; Department of General Surgery, Institute Gustave Roussy, Villejuif.
Transfer Laboratory of Biological Oncology, Public Assistance Hospitals of Marseille, Northern Faculty of Medicine, Marseille.
Mol Clin Oncol. 2015 Mar;3(2):295-298. doi: 10.3892/mco.2014.459. Epub 2014 Nov 20.
The presence of the Epstein-Barr-virus (EBV) has been reported to be a pathogenic factor in breast cancer (BC). We previously demonstrated the aggressiveness of EBV-positive BC. The purpose of the present study was to evaluate the effect of EBV on the prognosis of BC according to the BC phenotype. A total of 117 patients with primary BC previously tested for the presence of EBV were evaluated. The presence of the virus was evaluated in breast specimens using quantitative PCR (qPCR). Disease-free survival (DFS) and overall survival (OS) were evaluated for 4 molecular subtypes, namely luminal A and B (lumA and lumB, respectively), human epidermal growth factor receptor 2 (HER2) and triple-negative (TN) subtypes and according to the EBV status. EBV positivity was observed in 32.5% of the cases. TN, HER2 and lumB tumours were more frequent among EBV-BC cases (P=0.02). The DFS rates were different between BC subtypes (P=0.002), but the differences were not statistically significant when the cases were stratified according to the EBV status (P=0.08 for EBV-negative and 0.06 for EBV-positive cases). The OS rates were similar for BC subtypes (P= 0.50) and when the cases were stratified according to the EBV status (P=0.16 and P=0.67 for EBV-positive and -negative cases, respectively). EBV was not associated with DFS or OS, in contrast to BC phenotypes, tumour size or nodal status. Therefore, EBV positivity was found to exert no effect on survival, despite its association with aggressive BC phenotypes.
据报道，爱泼斯坦-巴尔病毒（EBV）的存在是乳腺癌（BC）的致病因素。我们之前证明了EBV阳性乳腺癌的侵袭性。本研究的目的是根据乳腺癌表型评估EBV对乳腺癌预后的影响。对总共117例之前检测过EBV存在情况的原发性乳腺癌患者进行了评估。使用定量聚合酶链反应（qPCR）在乳腺标本中评估病毒的存在情况。对4种分子亚型，即管腔A型和B型（分别为lumA和lumB）、人表皮生长因子受体2（HER2）和三阴性（TN）亚型，并根据EBV状态评估无病生存期（DFS）和总生存期（OS）。在32.5%的病例中观察到EBV阳性。TN、HER2和lumB肿瘤在EBV阳性乳腺癌病例中更为常见（P=0.02）。乳腺癌各亚型之间的DFS率不同（P=0.002），但根据EBV状态进行分层时，差异无统计学意义（EBV阴性病例P=0.08，EBV阳性病例P=0.06）。乳腺癌各亚型的OS率相似（P=0.50），根据EBV状态进行分层时也是如此（EBV阳性和阴性病例分别为P=0.16和P=0.67）。与乳腺癌表型、肿瘤大小或淋巴结状态不同，EBV与DFS或OS无关。因此，尽管EBV阳性与侵袭性乳腺癌表型相关，但发现其对生存率没有影响。
